Equinom announces $35 million in funding led by Synthesis Capital
Investors also included Praesidium, Bunge Ventures, BayWa, CPT Capital, Fortissimo, Phoenix.
Equinom, the company on a mission to cultivate better food from the ground up, has announced a $35 million tranche of funding to bring more of its optimized plant protein ingredients to market. The capital raise was led by Synthesis Capital (Synthesis), a global food technology and alternative protein investor, with additional investment from Praesidium, Bunge Ventures (the for-profit global investment arm of Bunge), BayWa, CPT Capital, and returning investors Fortissimo and Phoenix. This brings the total funding for Equinom to over $71 million to date.
With expertise in food, technology, and agriculture, Equinom breeds new non-GMO varieties of the plant-based food industry’s primary source crops including pea and soy, optimized specifically for food, so they require only minimal processing, thereby improving taste and nutrition and reducing cost and complexity. This is made possible by the company’s proprietary Manna technology platform which uses advanced algorithms to characterize the biochemical and genomic traits in a vast array of seed varieties, enabling the development of new ingredients with desirable traits for food production (such as mild taste, light color, high protein, etc.)—all without genetic modification. As a result, these new minimally processed plant proteins enable food companies to develop offerings that meet consumer demand for tastier and more affordable sustainable alternatives to meat and dairy.